PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.305
https://www.valueinhealthjournal.com/article/S1098-3015(19)32683-X/fulltext
Title :
PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32683-X&doi=10.1016/j.jval.2019.09.305
First page :
Section Title :
Open access? :
No
Section Order :
10247